(NASDAQ: BOLT) Bolt Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.86%.
Bolt Biotherapeutics's earnings in 2026 is -$29,580,000.On average, 6 Wall Street analysts forecast BOLT's earnings for 2026 to be -$40,604,632, with the lowest BOLT earnings forecast at -$62,708,417, and the highest BOLT earnings forecast at -$22,395,863. On average, 4 Wall Street analysts forecast BOLT's earnings for 2027 to be -$53,625,555, with the lowest BOLT earnings forecast at -$74,572,172, and the highest BOLT earnings forecast at -$30,506,798.
In 2028, BOLT is forecast to generate -$83,515,529 in earnings, with the lowest earnings forecast at -$80,240,410 and the highest earnings forecast at -$85,971,868.